Verona Pharma plc - American Depositary Shares (VRNA)

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

The company is working to launch its COPD treatment more broadly. The drug is a non-steroidal nebulizer.

The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.

GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks.

VRNA stock results show that Verona Pharma missed analyst estimates for earnings per share the second quarter of 2024.

The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales.

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.

The companies are closing in on the finish line for two new COPD treatments.

VRNA stock results show that Verona Pharma missed analyst estimates for earnings per share the first quarter of 2024.

The healthcare sector is no slouch when it comes to top-performing growth stocks.

Don't be surprised if these three stocks take off in the new year.